ALBUQUERQUE, N.M. and TORONTO, Aug. 23, 2011 /PRNewswire/ -- VeraLight Inc., the first company to develop an optical skin measurement for noninvasive diabetes screening, and Pear Healthcare Solutions Inc., a leading provider of in-pharmacy health screening and education services, today announced an agreement for the distribution of the SCOUT DS device in pharmacies across Canada.
"Since gaining our Health Canada License Approval and European CE Mark, we have been thrilled with the level of interest in distributing SCOUT DS outside of the United States," said David Van Avermaete, CEO of VeraLight. "After an extensive review, we chose Pear as our partner to bring the SCOUT DS to Canadian pharmacies based on its track record as a respected provider of high quality testing services and education for consumers on behalf of pharmacies, pharmaceutical and device companies."
"We at Pear Healthcare Solutions are proud to have been selected by VeraLight as its first distribution and education partner," said Mark Doyle, Vice President of Sales and Marketing for Pear. "I am confident that by providing this technology to Canadian pharmacies, we can make a positive difference in the healthcare system and in people's lives. The potential to identify people with undiagnosed diabetes or prediabetes could reduce long-term healthcare costs and improve the quality of lives for Canadians. We will introduce the device with screening events in two pharmacies in Ontario in August and expand across the country in the coming months." More information is available at http://www.pearhealthcare.com.
About SCOUT DS®
The SCOUT DS is the first noninvasive test that can replace conventional blood-based diabetes screening. The easy to operate SCOUT DS device needs no blood and does not require fasting. The patient simply places a forearm on the portable table-top unit, and a quantitative result is reported in about three minutes. SCOUT DS is Indicated for Use for the noninvasive screening of individuals 18 years or older who are at risk for prediabetes and/or type 2 diabetes to determine whether diagnostic testing is necessary. Prediabetes is defined as impaired glucose tolerance.
VeraLight is a privately held medical instrumentation company led by former Johnson & Johnson executive David Van Avermaete. The company's mission is to help stem the tide of the global diabetes epidemic through early detection of the more than 500 million individuals who have undiagnosed diabetes or impaired glucose tolerance, thus enabling initiation of therapies that can prevent diabetes or reduce its complications and associated costs. For information and a product video see http://www.veralight.com.
Pear Healthcare Solutions is a privately held company specializing in the development and implementation of programs to address the evolving needs of pharmacists in their expanding role of providing healthcare and disease management services. For more information visit http://www.pearhealthcare.com.
Pear Healthcare Solutions
SOURCE VeraLight Inc.